Literature DB >> 20383269

Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Aravind Ramakrishnan1, Brenda M Sandmaier.   

Abstract

The myeloproliferative neoplasms (MPNs) are a group of clonal disorders that arise from a pluripotent hematopoietic stem cell and are characterized by excess cellular proliferation. These disorders tend to be chronic in nature and can terminate over time into a bone marrow failure syndrome characterized by marrow fibrosis or transform into a leukemic phase. MPNs are predominantly diseases of the elderly and this is one reason why until very recently the standard treatment was supportive care. The only curative modality for these disorders is allogeneic hematopoietic cell transplantation. The introduction of reduced-intensity conditioning regimens now allows this life-saving therapy to be offered to elderly patients who were previously considered ineligible for high-dose conditioning owing to age or comorbidity. In this review, we will summarize the current strategies and future directions regarding the use of reduced-intensity conditioning regimens in the treatment of MPNs.

Entities:  

Keywords:  JAK-2; bcr–abl; graft-versus-leukemia; myeloproliferative neoplasm; reduced-intensity conditioning; stem cell transplant

Mesh:

Year:  2010        PMID: 20383269      PMCID: PMC2850074          DOI: 10.1586/ehm.09.73

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  106 in total

Review 1.  Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.

Authors:  A M Carella; S Giralt; S Slavin
Journal:  Haematologica       Date:  2000-03       Impact factor: 9.941

2.  Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells.

Authors:  Danila Valmori; Valeria Tosello; Naira E Souleimanian; Emmanuelle Godefroy; Luigi Scotto; Yu Wang; Maha Ayyoub
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

Review 3.  Reduced-intensity conditioning transplantation in myeloid malignancies.

Authors:  Rainer Storb
Journal:  Curr Opin Oncol       Date:  2009-06       Impact factor: 3.645

Review 4.  Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.

Authors:  R Champlin; I Khouri; S Kornblau; F Marini; P Anderlini; N T Ueno; J Molldrem; S Giralt
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

5.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Authors:  Damian J Green; John M Pagel; Eneida R Nemecek; Yukang Lin; Aimee Kenoyer; Anastasia Pantelias; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Joseph G Rajendran; Ajay K Gopal; Steven I Park; Oliver W Press
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

6.  Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  John M Pagel; Theodore A Gooley; Joseph Rajendran; Darrell R Fisher; Wendy A Wilson; Brenda M Sandmaier; Dana C Matthews; H Joachim Deeg; Ajay K Gopal; Paul J Martin; Rainer F Storb; Oliver W Press; Frederick R Appelbaum
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

7.  Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

Authors:  John Koreth; Kristen E Stevenson; Haesook T Kim; Michael Garcia; Vincent T Ho; Philippe Armand; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

8.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Authors:  Holbrook E Kohrt; Brit B Turnbull; Kartoosh Heydari; Judith A Shizuru; Ginna G Laport; David B Miklos; Laura J Johnston; Sally Arai; Wen-Kai Weng; Richard T Hoppe; Philip W Lavori; Karl G Blume; Robert S Negrin; Samuel Strober; Robert Lowsky
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Nicolaus Kröger; Ernst Holler; Guido Kobbe; Martin Bornhäuser; Rainer Schwerdtfeger; Herrad Baurmann; Arnon Nagler; Wolfgang Bethge; Matthias Stelljes; Lutz Uharek; Hannes Wandt; Andreas Burchert; Paolo Corradini; Jörg Schubert; Martin Kaufmann; Peter Dreger; Gerald G Wulf; Hermann Einsele; Tatjana Zabelina; Hans Michael Kvasnicka; Jürgen Thiele; Ronald Brand; Axel R Zander; Dietger Niederwieser; Theo M de Witte
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

Review 10.  The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.

Authors:  Huichun Zhan; Jerry L Spivak
Journal:  Clin Adv Hematol Oncol       Date:  2009-05
View more
  3 in total

1.  Generation of hydrogen peroxide-resistant murine neuroblastoma cells: a target discovery platform for novel neuroprotective genes.

Authors:  Annette E Maczurek; Rebekka Wild; Daunia Laurenti; Megan L Steele; Lezanne Ooi; Gerald Münch
Journal:  J Neural Transm (Vienna)       Date:  2013-02-20       Impact factor: 3.575

2.  Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients.

Authors:  Gina Zini; Marie C Béné
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

Review 3.  Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Authors:  Madappa N Kundranda; Raoul Tibes; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.